The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl.2F5 macrophage cell line. The cellular IC 50 value of imatinib for FMS was similar to those for BcrAbl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.
Protein kinases have become established targets for pharmacological intervention following the successful treatment of certain cancers with the kinase inhibitors imatinib and gefitinib (Buchdunger et al., 1996; Druker et al., 2001; Lynch et al., 2004; Paez et al., 2004) and the successful use of rapamycin to prevent kidney rejection after transplantation (Cohen, 2002) . Imatinib is an ATP analogue that inhibits the intracellular tyrosine kinases Abl and Arg as well as KIT and PDGF receptor kinases with similar efficiency . In chronic myeloid leukaemia (CML), imatinib inhibits catalytic activity by binding to the inactive form of the Bcr-Abl kinase domain, thereby preventing its conversion into its active oncogenic form (Schindler et al., 2000) . Similarly, imatinib binds to autoinhibited inactive KIT and is an effective treatment for gastrointestinal stromal tumours that have oncogenic mutations of the juxtamembrane regions of the KIT or PDGFa receptors (Longley et al., 2001; Joensuu et al., 2002; Ma et al., 2002; Zermati et al., 2003) . However, imatinib cannot inhibit KIT receptors with oncogenic mutations of Asp 816 (Frost et al., 2002; Ma et al., 2002) , most probably because these mutations stabilize the active form of KIT to which imatinib cannot bind (Dibb et al., 2004; Mol et al., 2004) .
KIT and PDGF receptors are members of the PDGF receptor family that includes FLT3 and FMS, which are resistant to imatinib . The resistance of FLT3 to imatinib is due to the presence of phenylalanine at position 691 instead of the threonine found in the imatinib-sensitive KIT and PDGF. Elegantly, replacement of Phe 691 of FLT3 with Thr confers imatinib sensitivity (Bohmer et al., 2003) . FMS, the receptor for macrophage colony stimulating factor (M-CSF or CSF-1) (Sherr et al., 1985) is more closely related to the KIT and PDGF receptors than FLT3 and furthermore its kinase domain sequence gives no obvious clue as to why FMS should be resistant to imatinib. Here, we report that FMS kinase activity and downstream signalling can be inhibited by imatinib at concentrations that are achieved in patients and we demonstrate that mutation of Asp 802 of FMS confers imatinib resistance. Figure 1a confirms that imatinib inhibits the phosphorylation of ERK and Akt in response to stem cell factor activation of the KIT receptor expressed by the murine haemopoietic FDC-P1 cell line (Caruana et al., 1993; Baker et al., 1994; Frost et al., 2002) . As expected, imatinib did not inhibit ERK phosphorylation in the Ml cell line in response to FLT3 ligand (Figure 1b) . The FDC-P1 cell line used here ectopically expresses human FMS (Dibb et al., 1990) and Figure 1c shows that imatinib treatment inhibited ERK and AKT phosphorylation in response to M-CSF. SCF/KIT stimulation of Erk and Akt phosphorylation was more sensitive to imatinib, but there was obvious inhibition of FMS signalling at 1 mM imatinib.
The effect of imatinib upon the phosphorylation and ubiquitination of normal human FMS expressed by Rat-2 fibroblasts (Figure 2a ) was compared to fibroblasts expressing a mutant D802VY708F FMS receptor (Figure 2b ), which has an oncogenic mutation of Asp 802 to Val that would be expected to confer imatinib resistance (Frost et al., 2002; Ma et al., 2002) . Normal FMS was maximally phosphorylated and ubiquitinated after treatment with M-CSF for 5 min and the IC 50 value for imatinib inhibition of these events was 0.3 mM, as calculated from densitometry readings of Figure 2a and two further repeats gave the same IC 50 value. An experiment performed in parallel shows that phosphorylation of the mutant D802VY708F receptor was resistant to imatinib with an IC 50 >4 mM (Figure 2b ). Since the D802V mutant receptor is oncogenic (Glover et al., 1995) , it was phosphorylated and ubiquitinated in the absence of M-CSF ( Figure 2b ). An in vitro kinase assay ( Figure 2c ) revealed similar inhibition of FMS but not of FMS D802VY708F kinase activity by imatinib.
Stimulation of Rat-2 fibroblasts that express FMS with M-CSF for 3 h alters their content of immature and mature forms of the FMS receptor ( Figure 2d ). This is because M-CSF increases the degradation rate of the mature receptor and therefore reduces its steady-state level We next assayed the effect of imatinib upon the proliferation of a number of different cell lines. The haemopoietic cell line FDC-P1 is often used to assay transformation (Wheeler et al., 1987) and although their proliferation is normally dependent upon IL-3, they can be stimulated to grow by M-CSF if they express recombinant FMS (Rohrschneider and Metcalf, 1989; Dibb et al., 1990) . Figure 3a shows that 0.5 mM imatinib 6 Rat-2 fibroblasts expressing FMS (a) or the mutant D802VY708F FMS (b) were starved of FCS overnight and then incubated with the indicated concentrations of imatinib for 3 h and stimulated in the presence of imatinib with 5 Â 10 3 U/ml M-CSF for 5 min and the cell lysates were used for immunoprecipitation with a FMS antibody . Samples were analysed by Western blotting and probed with an antiphosphotyrosine antibody (PY99, Santa Cruz), an antiubiquitin antibody (Chemicon) and for total FMS, as indicated. (c) FMS was immunoprecipitated from unstimulated lysates of 5 Â 10 6 Rat-2c-fms fibroblasts and an in vitro kinase assay was performed in the presence of varying concentrations of imatinib. FMS phophorylation was assayed by SDS-PAGE autoradiography D, Rat-2c-fms fibroblasts expressing FMS were incubated with the indicated concentrations of imatinib and with 5 Â 10 3 U/ml M-CSF for 3 h and total cell lysates were analysed by Western blotting with anti-FMS.
inhibited the proliferation of FDC-P1 cells expressing normal human FMS (FD-cfms) in response to M-CSF and that no growth was observed in the presence of 2 mM imatinib. The concentration of imatinib at which 50% inhibition of growth occurred (cellular IC 50 ) compared to untreated cells was calculated from Figure 3a as 0.6 mM. In contrast, the proliferation of FDC-P1 cells expressing the mutant receptor FMS D802V (FD D802V) was largely unaffected by imatinib. As expected, FD-c-fms cells that were stimulated to grow by IL-3 were resistant to imatinib (data not shown). The mutant V-fms and D802V mutant FMS receptors are oncogenic and for this reason can stimulate the growth of FDC-P1 cells in the absence of M-CSF (Wheeler et al., 1987; Baker et al., 1994; Glover et al., 1995) . However, Figure 3a shows that unlike D802V, the oncogenic mutations suffered by the oncogene v-fms (Roussel et al., 1988; Woolford et al., 1988) do not confer strong 4 cells/ml in RPMI þ 10% FCS in 24-well plates and grown for 7 days in the indicated concentrations of imatinib (stock solutions prepared in water), after which time viable cell numbers were counted. FD c-fms cells were stimulated to grow by 5 Â 10 3 U/ml M-CSF. (b) 1Â 10 4 Bacl.2F5 cells and Bacl.2F5 cells that express FMS D802VY708F were separately plated in DMEM þ 10% FCS þ 5 Â 10 3 U/ml M-CSF in 24-well trays and grown for 4 days in the indicated concentrations of imatinib, after which viable cell numbers were counted using a haemocytometer and triplicate assays were averaged. Bacl.2F5 cells were infected with a D802VY708F retroviral construct following CaPO 4 transfection of the packaging cell line PA317. Infected cells were selected with G418 (1 mg/ml). (c) 1 Â 10 4 cells Rat-2 fibroblasts expressing V-fms, (Rat-2 v-fms) FMS (Rat-2 c-fms) and FMS D802VY708F were separately plated in DMEM þ 10% FCS and grown for 5 days in the indicated concentrations of imatinib, after which viable cell numbers were measured. Rat-2 c-fms were plated with or without 5 Â 10 5 U/ml M-CSF. For all experiments, triplicate assays were averaged. Giemsa staining of: (d) Rat-2 v-fms, (e) Rat-2 v-fms þ 1 mM imatinib, (g) Rat-2 DV708F, (h) Rat2 DV708 þ 1 mM imatinib, (j) Rat-2 Src, (k) Rat-2 Src þ 1 mM imatinib and (l) Rat-2Src þ 1 mM SU6656. TRITC-Phalloidin staining: (f) Rat-2v-fms and (i) Rat-2v-fms þ 1 mM imatinib. Â 200 magnification, except Â 400 for (f and i). Rat-2 fibroblasts were plated at a density of 1 Â 10 4 cells/well in sterile glass multispot slides (CA Hendley, Essex; PH-005) and cultured with total 200 ml of culture medium overnight to allow anchorage. Adherent cells were treated overnight in fresh culture medium with or without 1 mM imatinib or 1 mM SU6656. Cells were washed in PBS, fixed in 4% paraformaldehyde for 10 min, permeabilized with 2% triton/PBS for 10 min and were either stained with either Giemsa (1:100, Sigma) for 15 min or were incubated with TRITC labelled Phalloidin (1:400, Sigma) for 30 min. Slides were washed in PBS and mounted in antifade.
imatinib resistance (IC 50 o2.0 mM). As expected, imatinib treatment inhibited the kinase activity of V-fms in vitro (data not shown).
Bacl.2F5 is a macrophage cell line whose growth is dependent upon M-CSF (Morgan et al., 1987) . Figure 3b shows that proliferation of these cells was abolished by 1 mM imatinib and that infection of this cell line with a retrovirus that expresses FMS D802V conferred imatinib resistance.
Rodent fibroblasts are routinely used to assay transformation. These cells proliferate in the presence of FCS and normally display contact inhibition. In the presence of M-CSF, rodent fibroblasts that express FMS (Rat-2cfms) become transformed and resistant to contact inhibition and so grow to a higher cell number (Roussel et al., 1987; Baker et al., 1994) . Figure 3c shows that the proliferation of Rat-2c-fms cells in the absence of M-CSF was relatively unaffected by imatinib. The addition of M-CSF enhanced cell numbers by about 75% and this increase was fully suppressed by 1 mM imatinib (Figure 3c) . Similarly, imatinib inhibited the enhanced proliferation of Rat-2 fibroblasts that express the oncogene v-fms (Figure 3c ). Figure 3d and e show that imatinib suppresses the characteristic transformed morphology of individual Rat-2v-fms fibroblasts. This inhibitory effect of imatinib upon the transformed morphology of fibroblasts is also readily apparent by actin staining (Figure 3f and i) . Higher magnifications of Figure 3f and i show that imatinib treatment causes an increase in actin cable formation (data not shown). Expression of FMS D802V only partially transforms Rat-2 fibroblasts and only when combined with a second site mutation (Tyr 708 to Phe) that enhances receptor stability . Nevertheless, Figure 3c shows that Rat-2 D802VY708F has elevated proliferation compared to control Rat-2c-fms cells in the absence of M-CSF and this growth advantage becomes particularly evident in the presence of 1 and 2 mM imatinib. Figure 3g and h shows that the transformed morphology of Rat-2 D802VY708F fibroblasts is not altered by imatinib treatment. Similarly, the morphology of Rat-2 fibroblasts that are transformed by Src (Figure 3j ) was unaffected by imatinib treatment (Figure 3k ), in contrast to the effect of the Src kinase inhibitor SU6656 (Figure 3l ). These results demonstrate that imatinib can fully suppress transformation of rodent fibroblasts by normal FMS and by oncogenic V-Fms but cannot suppress transformation by FMS D802VY708F or Src.
We have shown that imatinib inhibits the phosphorylation, ubiquitination and downregulation of normal FMS and inhibits its activation of downstream signalling pathways. As further confirmation, we found that mutation of Asp 802 to Val of FMS conferred imatinib resistance. This mutation and the equivalent mutation of Asp 816 of KIT most probably stabilize the active kinase domain structure (Dibb et al., 2004) , to which imatinib does not bind .
Imatinib inhibited FMS with a biochemical IC 50 of 0.3 mM (Figure 2a ) which is very similar to the biochemical IC 50 values for the KIT and PDGF receptors and considerably less than the value of >10 mM that was originally described . The plasma concentration of imatinib ranges from 4.5 to 1.5 mM over 24 h in patients treated daily with 400 mg of this drug (Druker et al., 2001) . This level of imatinib is significantly above the cellular IC 50 values that we observed for imatinib inhibition of cell growth in response to M-CSF.
In accord with our results, imatinib inhibits human macrophage colony production in vitro (Dewar et al., 2003) . This was initially ascribed to the inhibition of a kinase other than FMS, but a recent report now implicates FMS as the most likely target (Dewar et al., 2005) . These authors report IC 50 values of 1.42 and 1.86 mM for imatinib inhibtion of FMS phosphorylation and of M-CSF-dependent cell growth, respectively (Dewar et al., 2005) . We found significantly lower IC 50 values that were comparable to other members of the PDGF receptor family and this together with our identification of an imatinib resistant FMS D802V mutant firmly establishes FMS as a sensitive target of imatinib. Importantly, the haemopoietic, fibroblast and macrophage proliferation assays that we use demonstrate that the cellular IC 50 of 0.6 mM for imatinib inhibition of FMS (Figure 3a) is similar to the cellular IC 50 of 0.4 mM reported for Bcr-Abl (Mahon et al., 2000; Corbin et al., 2003) and 0.3 mM for Kit (Krystal et al., 2000) , which strongly indicates that the inhibitory effects of imatinib upon Bcr-Abl and KIT in patients can also be achieved for FMS. Although FMS is not thought to be commonly mutated in cancer (Reilly, 2002) , autocrine expression of normal FMS and M-CSF is implicated in the development of ovarian and breast cancers (Kacinski, 1997; Lin et al., 2001) . In mice, M-CSF and FMS are important for the activity of osteoclasts, macrophages and microglial cells (Pollard, 1997) . Over-activity of these cell types is strongly implicated in certain aspects of a number of medical conditions including metastasis, osteolysis, osteoporosis, inflammation and neurodegenerative diseases (Aldskogius, 2001; Mundy, 2002; Murray et al., 2003; Sweet and Hume, 2003; Perry, 2004; Pollard, 2004) . Consequently, our results considerably broaden the therapeutic potential of imatinib.
